NTRA Natera, Inc.
Legal ·
A jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit.
Natera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones.
Natera is a diagnostics company that applies proprietary molecular and bioinformatics technology, centered on cell-free DNA, to disease management. It focuses on oncology, women's health and organ health. In oncology it sells Signatera, a personalized blood-based circulating tumor DNA test used to detect molecular residual disease and monitor recurrence. In women's health, its Panorama test is a noninvasive prenatal test that the company believes is the most accurate such test commercially available in the United States. In organ health it offers tests that measure donor-derived cell-free DNA to assess heart, lung and kidney transplant rejection. In December 2025 Natera acquired Foresight Diagnostics, adding ctDNA-based MRD tests and expanding into lymphoma. Revenues were $2,306.1 million in 2025, and the company processed approximately 3.5 million tests that year. Its Constellation cloud software lets laboratories run its algorithms locally, and it works with over 100 laboratory and distribution partners.
| Product or program | What it is | Stage |
|---|---|---|
| Signatera | Personalized ctDNA test for molecular residual disease and recurrence monitoring | |
| Panorama | Noninvasive prenatal test | |
| Donor-derived cell-free DNA tests | Measure transplant rejection of heart, lung and kidney | |
| Foresight MRD tests | ctDNA-based MRD tests using phased variants, acquired December 2025 | |
| Constellation | Cloud software that lets laboratories run its algorithms locally |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $624.1 million | $404.1 million |
| Net income (loss) | -$208.2 million | -$190.4 million |
| Cash from operations | $215.3 million | $135.7 million |
| Cash and equivalents | $1.08 billion | $945.6 million |
| Short-term investments | $22.7 million |
Natera, Inc. trades under the ticker NTRA on NASDAQ.
Natera, Inc. is listed on NASDAQ. Our directory also records these other listings: BCBA:NTRA; BCBA:NTRA.CI; BCBA:NTRAD; BIVA:NTRA; BMV:NTRA; DUS:45E; FWB:45E; GETTEX:45E; HAM:45E; HAN:45E; LS:A14VPJ; LSX:A14VPJ; MUN:45E; TRADEGATE:45E; XETR:45E.
The SEC Central Index Key (CIK) for Natera, Inc. is 1604821. Its filings are on SEC EDGAR.
144,144,170 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Natera, Inc. under United States.
Our directory classifies Natera, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Natera, Inc. is US6323071042.
aibio.space lists Natera, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Natera is a diagnostics company that applies proprietary molecular and bioinformatics technology, centered on cell-free DNA, to disease management. It focuses on oncology, women's health and organ health.
Signatera: Personalized ctDNA test for molecular residual disease and recurrence monitoring
Panorama: Noninvasive prenatal test
Natera, Inc. reported a net loss of $208.2 million for the fiscal year ended Dec 31, 2025, and generated $215.3 million of cash from operations, per its annual report to the SEC.
$624.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.09 billion in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio